10T Holdings CEO: Bitcoin Could Easily Reach $200,000 Amid ETFs and Halving
Bitcoin could easily rise to $200,000 with increased demand for bitcoin from ETFs and the upcoming halving supply shock, 10T Holdings CEO Dan Tapiero said in an interview at the Digital Asset Summit in London.
That would be around three times the current price, roughly equivalent to the percentage difference between the 2017 and 2021 peaks, Tapiero explained. He added that Bitcoin rose about 20 times from the bear market lows to the 2021 peak, meaning it could rise to the $300,000 mark if the previous cycle is repeated. It's hard to make definitive statements about these things, and the timing is difficult," he said. I think in general we're going to get there in the next 18 to 24 months, and probably sooner".
As for ethereum, Tapiero believes there will likely be ethereum spot ETFs as the underlying assets have been built up and reach network effect , though he's not sure when those plans will be approved.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
Crypto prices
More
